An extremely potent and highly specific nonpeptide, subnanomolar endothelin (ET) receptor antagnist, SB 209670, has been synthesized and characterized. SB 209670, which was rationally designed using conformational models of ET-1, selectively inhibits binding of 12SI-labeled ET- Endothelin-1 (ET-1) is a potent endothelium-derived vasoconstrictor peptide (1). ET-1 has pronounced effects on the cardiovascular system and, in particular, on the coronary, renal, and cerebral circulatory beds. Elevated or abnormal biosynthesis/release of ET-1 may therefore be a factor in the pathogenesis of certain diseases. Two ET receptor subtypes, designated ETA and ETB, have been cloned and sequenced (2, 3). The ETA receptor is characterized by marked selectivity for ET-1 over the isopeptides ET-3 and sarafotoxin 6c (S6c), a snake venom toxin. The primary effects mediated by the ETA receptor include vasoconstriction and vascular smooth muscle cell proliferation (4-7). In contrast, the ETB receptor is characterized as exhibiting equivalent affinity toward ET-1, and S6c (3, 8) and mediates the release of nitric oxide (9, 10), vasoconstriction ofcertain vascular beds, and bronchoconstriction (11-13).
nM, respectively). SB 209670 produces concentrationdependent inhibition of ET-1-mediated vasoconstriction in isolated vascular tissues and in vivo following either intravenous or intraduodenal admiration. SB 209670 produces a dose-dependent reduction in blood pressure in hypertensive rats, protects from ischemla-induced neuronal degeneration in a gerbil stroke model, and attenuates neointima formation following rat carotid artery balloon aoplat. SB Endothelin-1 (ET-1) is a potent endothelium-derived vasoconstrictor peptide (1) . ET-1 has pronounced effects on the cardiovascular system and, in particular, on the coronary, renal, and cerebral circulatory beds. Elevated or abnormal biosynthesis/release of ET-1 may therefore be a factor in the pathogenesis of certain diseases. Two ET receptor subtypes, designated ETA and ETB, have been cloned and sequenced (2, 3) . The ETA receptor is characterized by marked selectivity for ET-1 over the isopeptides ET-3 and sarafotoxin 6c (S6c), a snake venom toxin. The primary effects mediated by the ETA receptor include vasoconstriction and vascular smooth muscle cell proliferation (4) (5) (6) (7) . In contrast, the ETB receptor is characterized as exhibiting equivalent affinity toward ET-1, ET-3, and S6c (3, 8) and mediates the release of nitric oxide (9, 10), vasoconstriction ofcertain vascular beds, and bronchoconstriction (11) (12) (13) .
Exogenous administration of ET produces pronounced, long-lasting vasoconstriction and smooth muscle cell proliferation in vitro and in vivo (1, (12) (13) (14) (15) (16) , but evidence implicating ET as an endogenous mediator of these biological phenomena is still limited and largely indirect. The development of potent and selective ET receptor antagonists will facilitate definition of the role of ET in pathological conditions. This report describes the characterization of SB 209670, which was rationally designed using conformational models of the natural ligand and, to our knowledge, is the most potent (subnanomolar) nonpeptide ET receptor antagonist identified to date.
Screening In Vitro ET Antagonist Activity. In vitro vascular reactivity was determined in ring segments of endothelium-denuded rat thoracic aorta or rabbit pulmonary arteries suspended in organ chambers filled with Krebs/bicarbonate solution (370C and aerated with 95% 02/5% C02) (16, 17) . Cumulative concentration-response curves were constructed in the presence of antagonist or vehicle following a 30-min pretreatment period. Contractile responses are expressed as a percentage of the response elicited by 60 mM KCl.
In Vivo ET Antagonist Activity. Male Sprague-Dawley rats (14) . In a separate series of experiments male SpragueDawley rats (300 g) were anesthetized and catheters were placed in a femoral artery (for blood pressure measurement), a femoral vein (for administration of ET-1), and the duodenum (for drug administration). Three days following surgery blood pressure was monitored in conscious freely moving rats. The increase in blood pressure in response to repeated i.v. boluses of ET-1 (0.2 nmol/kg, every 30 min) was measured before and after administration of vehicle.
Animal Disease Models. Systemic arterial blood pressure was measured in chronically instrumented conscious freely moving spontaneously hypertensive rats (18) . Rats were allowed at least 3 days to recover from surgery prior to any experimentation. On the day of the experiment, either vehicle or SB 209670 was administered intraduodenally. Cardiovascular parameters were recorded continuously for 48 hr.
Bilateral carotid artery ligation was used to produce transient forebrain global ischemia (6.5 min) in male Mongolian gerbils (70 g) under 2.5% isoflurane anesthesia (19) . Animals were placed on heating pads to maintain body temperature at 37°C. SB 209670 was administered intracerebroventricularly 5 min pre-and 60 min post-occlusion. A sham group underwent similar manipulations but without ischemia. Gerbils were allowed to recover for 7 days, and following sacrifice CA1 neuronal counts were performed in a blinded fashion on 750-,um-thick hippocampal sections.
Left common carotid artery balloon angioplasty was performed in anesthetized male Sprague-Dawley rats (350 g) (20) . Rats were treated either with vehicle or SB 209670 3 days prior to surgery and dosing was continued for a subsequent 14 days, at which time the animals were sacrificed. Neointima formation was quantified, by a histologist blinded to the treatment, from 8-,um arterial cross sections of perfusion-fixed vessels using a Bioscan (Washington, DC) Optimus cell imaging system.
All experiments were performed in accordance with the guidelines of the Animal Care and Use Committee, SmithKline Beecham Pharmaceuticals, and the American Association of Laboratory Animal Care.
Statistics. Values are means + SEM and n represents the number of animals or separate experiments studied in a particular group. Statistical comparisons were made by an unpaired Student's t test, with a P value <0.05 accepted as significant.
RESULTS
SB 209670 is a potent inhibitor of 125I-ET-1 binding to cloned human ETA and ETB receptors (Fig. 1) . Binding of 125I-ET-1 to human ETA or ETB receptor clones is specific, saturable, and of high affinity. The apparent dissociation constant (Kd) and maximum binding (Bn) 
SB 209670 produces parallel rightward shifts in the concentration-response curve to ET-1 in isolated rat aorta (ETAmediated: ref. 7) with a Kb value of 410 ± 40 pM (Fig. 2) . The maximal contractile response to ET-1 is not affected by SB 209670 at concentrations up to 1 p.M. At higher concentrations, SB 209670 competitively antagonizes ET-1-induced contraction mediated by ETB receptors in the isolated rabbit pulmonary artery (7) with a Kb value for inhibition of 199 ± 9 nM (Fig. 2) . SB 209670 produces similar inhibition of S6c-stimulated vasoconstriction.
The selectivity of SB 209670 for ET receptors was assessed by investigating radioligand binding, contraction ofisolated rat aorta, and calcium mobilization by a variety of other receptor agonists in vascular smooth muscle cells (data not shown). SB The in vivo hemodynamic effects of SB 209670 were examined in conscious and anesthetized rats. Bolus i.v. administration of ET-1 (0.3 nmol/kg) produced a biphasic change in systemic arterial blood pressure in the anesthetized rat (Fig. 3A) . The initial vasodilator and secondary vasoconstrictor responses to ET-1 are believed to be mediated by the ETB and ETA receptors, respectively (14) . SB 209670 (18 pumol/kg, i.v.) eliminates the vasoconstrictor actions of ET-1 and antagonizes the increase in carotid and mesenteric vascular resistance in the anesthetized rat (Fig. 3A) . Additionally, SB 209670 inhibits the transient ETB-mediated carotid vasodilation and the associated decrease in systemic arterial blood pressure (Fig. 3A) . Intraduodenal administration of SB 209670 (18 ,umol/kg) also antagonizes the vasopressor response to exogenous ET-1 in conscious rats (Fig. 3B) ; inhibition is observed for 3.5 hr, with maximal inhibition occurring 1.5 hr following administration.
The availability of potent and orally active ET receptor antagonists has allowed us to evaluate a role for endogenous ET in disease models. In the spontaneously hypertensive rat, a model of essential hypertension, SB 209670 produces dose-dependent reductions in blood pressure following intraduodenal administration (Fig. 4A) . The antihypertensive effects are long-lasting, with blood pressure returning to control values 24-48 hr following drug administration. In a gerbil model of stroke, ischemia produces a 45% decrease in the number of neurons in the CA1 region in vehicle-treated animals (Fig. 4B) . Pretreatment with SB 209670 protects against ischemia-induced neuronal death. A dose of 50 yg administered intracerebroventricularly produces 94% neuronal protection. SB 209670 produced a 52% reduction in the degree of neointima formation following balloon angioplasty of the rat common carotid artery (Fig. 4C) . 
DISCUSSION
The present study describes the characterization of a nonpeptide ET receptor antagonist which was rationally designed using conformational models of a natural ligand, ET Indirect evidence supports a role for ET in the pathogenesis of several cardiovascular diseases. Changes in ET levels, ET receptor populations, and vascular reactivity have been associated with hypertension (24) . The observation that SB 209670 produces potent and long-lasting antihypertensive effects in a rat model of hypertension supports a causal relationship between ET and abnormal blood pressure regulation.
One of the consequences of chronic hypertension is abnormal vascular smooth muscle and myocardial remodeling. ET may be involved in the etiology of this chronic process because it is also a potent vascular smooth muscle mitogen in vitro (5, 15) . Furthermore, exogenous administration of ET promotes neointima formation following balloon angioplasty (25) . Evidence for a pathological role of ET in the genesis of neointima formation is suggested by the present study in which SB 209670 ameliorates the neointima formation following angioplasty. ET has a pharmacological profile that might be expected to contribute to neuronal injury associated with ischemic and hemorrhagic stroke (26) . SB 209670 affords significant protection in ischemia-induced stroke, supporting such a notion.
In summary, SB 209670 is a potent, highly selective, nonpeptide antagonist of ET receptors. Blockade of the actions of endogenous ET with SB 209670 produces an antihypertensive action and protection against neuronal degeneration following cerebral ischemia. In addition, the present data provide evidence that an ET receptor antagonist can inhibit angioplasty-induced neointima proliferation. The identification of this important pharmacological tool should prove invaluable in further establishing the role of ET in pathophysiology.
